title: [Renal neoplasms in children].
abstract: Nephroblastoma is the most common kidney tumor in Polish children.
  
  
  OBJECTIVE
  to present clinical material and outcome of 533 children with renal tumors.
  
  
  METHODS
  500 pts with nephroblastoma and 33 of non-Wilms: CMN, RCC,CSSK, RTK and others tumors were registered, mean age 4.5 years between 1993 till 2002. Stage: CS I--148, CS II--191, CS III--114, CS IV--51, CS V--29 pts. All pts with nephroblastoma were treated according to the first national PPGGL 01-92 protocol with pre-operative chemotherapy (ACT, VCR) for CS I-III and ACT, VCR, DOX in pts of stage IV, over the age of 6 months. Pre-operative chemotherapy was done to 93.8% pts.
  
  
  RESULTS
  Radical nephrectomy post pre op chemotherapy was performed in 451 (98%) pts over 6 months and in 44 (8.2%) infants less than 6 months with nephroblastoma. Partial nephrectomy for unilateral tumor post preoperative chemotherapy was made in 6 (1.2%). In 26/29 (89.65%) of CS V nephroblastoma kidney sparing surgery was possible, and in 12 uni-lateral nephrectomy was performed. Surgical complications were mild and occurred only in 8.9% pts.
  
  
  RESULTS
  5-years overall survival of CS I pts (favorable and standard histology) is 93.48%, CS II--96.8%, CS III--84.4%, CS IV--67%, CS V--58%. The results of treatment of 33 pts with non-Wilms renal tumors have improved lately. 78.7% of our pts achieved 5-years overall survival.
  
  
  CONCLUSIONS
  The use of systemic neoadjuvant chemotherapy in all pts over 6 months according to the recommendation of SIOP Nephroblastoma protocol (01-92) produced tumor shrinkage, facilitated complete surgical nephrectomy, and was very advantageous in the treatment of renal tumors in children. The results of treatment of non-Wilms tumor have also improved thanks to introduction of new and more aggressive regimens of chemotherapy.
authors.affiliation: Klinika Chirurgii i Urologii Dzieciecej Akademii Medycznej we Wrocławiu.
authors.forename: Krystyna
authors.initials: K
authors.lastname: Sawicz-Birkowska
authors.forename: Jerzy
authors.initials: J
authors.lastname: Czernik
authors.forename: Maciej
authors.initials: M
authors.lastname: Bagłaj
authors.forename: Piotr
authors.initials: P
authors.lastname: Czauderna
authors.forename: Sabina
authors.initials: S
authors.lastname: Kantorowicz-Szymik
authors.forename: Wojciech A
authors.initials: WA
authors.lastname: Poznański
authors.forename: Przemysław
authors.initials: P
authors.lastname: Mańkowski
authors.forename: Wojciech
authors.initials: W
authors.lastname: Madziara
authors.forename: Andrzej
authors.initials: A
authors.lastname: Prokurat
authors.forename: Jerzy
authors.initials: J
authors.lastname: Osemlak
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D008297:Male; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D009392:Nephrectomy / Q000379:methods; D011044:Poland; D011379:Prognosis; D012074:Remission Induction; D012189:Retrospective Studies; D012307:Risk Factors; D016019:Survival Analysis; D016896:Treatment Outcome; D009396:Wilms Tumor / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*